Previous 10 | Next 10 |
The psychedelics renaissance is in an expanded growth mode, not just in the U.S. and Canada, but in other countries as well. But everywhere in the world, it’s a bit of a Dr. Jekyll/Mr. Hyde scenario: startup businesses ostensibly building a serious moneymaking enterpr...
ATAI is backed by Peter Thiel. Its decentralized business model is pretty unique. I will wait for more data before I take a call on this very interesting company. Atai Life Sciences N.V. ( ATAI ) is a German-headquartered developer of medicines for mental health diso...
Today in the psychedelics industry there is a flurry of activity by some of the industry’s biggest donors, business developers, celebrities, and other movers and shakers who are not only upping their involvement in the industry today but also laser-focused on where it is goin...
Tech stocks have crashed, but Wall Street should eventually remember why the love affair began in the first place. After the tech crash, it makes sense to invest in a large quantity of names. Even so, this isn't an excuse to buy anything and everything. Don’t waste your tim...
Even while Compass has seen some steady progress in the clinic, its share price has nose-dived, sinking 72% over the past 12 months. The company hopes to bring a combination of the psychedelic drug psilocybin and psychological support to market. Psilocybin is currently classed as ...
A psychedelics company recently scored a major win after the Patent Trial and Appeal Board (PTAB) upheld a novel psychedelic patent that was under challenge. Compass Pathways PLC (NASDAQ: CMPS) , a mental healthcare company based in the United Kingdom, synthesized and patented a type of p...
Now that psychedelics have taken hold in the consciousness of medicine as an approach to better mental health—with psychedelics-assisted therapy showing mostly positive results in more clinical trials by more companies—maybe now is the time to accelerate the building o...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – June 15, 2022 – Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of mental health conditions. The Tesla CEO said ...
Palm Beach, FL – June 7, 2022 – FinancialNewsMedia.com News Commentary – The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still projected to continue to grow over the next years to come...
Shares of mental health biopharma Atai Life Sciences N.V. have fallen some two-thirds from their June 2021 IPO pricing as the biotech market continues to crater. The company’s approach of identifying (in many instances psychedelic) compounds that have been tested in previous hu...
News, Short Squeeze, Breakout and More Instantly...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...